本文介绍目前市面上已经获批或者在研的几款anti-HER2 ADC药物的载药信息和对ADC药物性质的影响,包括DS-8201、SYD985、RC-48、T-DM1、ARX788。 图1. ADC药物的作用机制24 ADC药物载药的结构和机制特点 ADC所携带的细胞毒性载荷药物是其最重要的效应成分,...
ADC药物不良反应可以分为在靶毒性和脱靶毒性(抗原依赖性毒性和抗原非依赖性毒性),前者是指ADC药物对表达靶抗原的正常组织产生杀伤效应而导致的毒性作用;后者则是指药物在不表达靶抗原的器官/细胞中产生的毒性作用。其中脱靶毒性是临床开发中ADC剂量限制性毒性(DLT)的主要原因[14]。并且不管是在靶毒性还是脱靶毒性,尽...
而将非结合对照ADC与曲妥珠单抗或培妥单抗联合给药后,活性很低。 活性的提高可能是由于与非重叠表位结合或Fc受体聚集增加了内化。 总结 XMT-2056靶向HER2的差异性表位,在联合应用中发挥出1+1>2的效果,同时利用STING 激动剂诱导Ⅰ型干扰...
Anti-HER2-ADC bei Brustkrebsdoi:10.1007/s15004-019-7256-8RedaktionSpringerOnkologieSpringerInFo Hmatologie + Onkologie
然而,根据报道,大多数ILD事件发生在抗肿瘤药物治疗的早期,例如通常在免疫检查点抑制剂(ICIs)治疗的2个月内和anti-HER2 ADC治疗的12个月内。在应用anti-HER2 ADC治疗的情况下,ILD发生率在12个月后降到7%,在18个月后降到1.4%。 >>> 疑似DIILD的诊断关键考量...
Development strategy of ENHERTU(trastuzumab deruxtecan)—anti-HER2 antibody–drug conjugate— Antibody-drug conjugate(ADC) represents a promising class of pharmaceutical with a wide therapeutic index due to highly efficient and selective drug delive... Takashi Nakada,Norihiro Nishimoto,Ayako Arai,......
Similar results on HER237 and TF38 (tissue factor) specific antibody-drug conjugates (ADC) have been reported by comparing the ADC efficacy on cultured cells in IgG and Fab form. However, the data also suggest that the bivalent enhancement of immunotoxin cytotoxicity is antibody-dependent, i.e...
ARX788 is an anti-HER2 antibody drug conjugate (ADC) developed using Ambrx proprietary Engineered Precision Biologics technology. The manufacturing process of ARX788 has been optimized during the course of early to late-phase clinical development. A comprehensive evaluation...
Preparation and Biological Activity of Anti-Her2 Antibody-MMAE Conjugate Object: To prepare an antibody drug conjugate( ADC) with Her2 antibody and MMAE. And to test the effect of this ADC on growth,apoptosis and cell cycle of breast cancer cell. Method: Anti-Her2 monoclonal antibody PH was ...
(21) 对研究过程可能用到的清淋药物或对症处理 CRS 的药物过敏或不耐受的患者,包括但不限于氟达拉滨和环磷酰胺或托珠单抗;已知对 anti-HER2-CAR-T 的成分过敏;或有任何严重的过敏史,例如,过敏性休克; (22) 给药前1个月内参加过其他干预性临床试验者; ...